Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 2016. The document serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibilities (PDMR) in accordance with DTR 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a regulatory disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing reports the acquisition of GSK Ordinary Shares by various Directors and PDMRs on April 14, 2016. These acquisitions were executed at a price of 1500.59 pence per Share and resulted from the reinvestment of dividends paid on Shares held through GSK's ShareReward Plan.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of specific share purchase events.
Important Facts for Investors
- Transaction Date: Shares were acquired on April 14, 2016.
- Share Price: The acquisition price was 1500.59 pence per Share.
- Transaction Type: All reported purchases were dividend reinvestments via the ShareReward Plan, not open market purchases.
- Participants: Transactions involved 11 individuals, including CEO Sir Andrew Witty (92 shares) and Company Secretary Mrs V A Whyte (89 shares).
- Scope: This filing contains no financial results or strategic updates.